- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00870415
Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer
Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery.
PURPOSE: This phase II trial is studying different breast-conserving surgery techniques in treating women with breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Evaluate the percentage of histologically healthy margins maintained during resection in women with breast cancer.
Secondary
- Evaluate local recurrence at 5 years.
- Evaluate aesthetic results.
- Evaluate quality of life using the QLQC30 and BR23 questionnaires.
OUTLINE: This is a multicenter study.
Patients undergo oncoplastic conservative surgery according to defined modalities across the various centers.
Quality of life is assessed periodically.
After completion of study treatment, patients are followed every 6 months for 2 years and then for at least 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
- Diagnosis of intraductal breast cancer requiring a wide local resection
- Diagnosis of infiltrating ductal breast cancer within range
- Diagnosis of invasive breast cancer that has not responded well to neoadjuvant treatment
- No multicentric tumor
- No gigantomastia
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- No patients subject to a measure of legal protection or unable to express consent
- No patients deprived of liberty by judicial or administrative decision or hospitalized without patient consent
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- No prior radiotherapy to the diseased breast
- No prior adjuvant treatment
- No concurrent participation in another clinical research study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Surgerie
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of histologically healthy margins maintained during resection
Time Frame: From inclusion to end of intervention
|
From inclusion to end of intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Philippe Rouanet, MD, PhD, Institut du Cancer de Montpellier - Val d'aurelle
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000633327
- CLCC-PHRC-OP-06
- CLCC-VA-2006/32
- CLCC-ID-RCB-2006-A00694-47
- INCA-RECF0638
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on therapeutic conventional surgery
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedSkin Basal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnAdult Spinal Cord Neoplasm | Spinal Bone Metastases | Spinal Cord Metastases
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; AIDS and Cancer Specimen ResourceCompletedHIV Infection | Anal Squamous Cell Carcinoma | Stage 0 Anal Canal Cancer | Stage I Anal Canal CancerUnited States
-
University of California, DavisNational Cancer Institute (NCI)CompletedPain | Breast Cancer | Perioperative/Postoperative ComplicationsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)UnknownBreast CancerUnited States
-
Roei Medical Technologies Ltd.Completed
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)CompletedBladder CancerUnited States, Canada
-
Institute of Cancer Research, United KingdomCompletedBladder CancerUnited Kingdom
-
Duke UniversityNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States